Sesen Bio Inc (SESN)

[the gipper]

Shorts are in deep trouble and their fear is well founded.
EBIO now has a Phase III oncoloby treatment well underway with the plurchase of "Vicinium which remains in Phase III trial for treatment of high-grade non-muscle invasive bladder cancer (NMIBC). NMIBC accounts for up to 80% of all bladder cancers and remains the sixth most common cancer globally. The United States recorded around 74,000 cases of NMIBC with 16,000 deaths in 2015.
In addition they also have Proxinium which is intended for treating late-stage squamous cell carcinoma of the head and neck, which is seventh most common form of cancers The drug is expected to start Phase II trials early next year. Proxinium has also secured Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and Fast Track designation from the FDA.

Eleven already has a couple of TPT candidates intended for treating a wider range of cancers. The acquisition creates a listed company working on developing TPT therapies in areas of oncology with substantial unmet medical needs.

Eleven’s earlier agreement with Roche for developing EBI-031 would progress as planned. The combined entity will benefit from capital cash flows generated from the partnership, including funding the development of Vicinium and Proxinium."


Read more: Eleven Biotherapeutics Acquires Viventia Bio | Investopedia http://www.investopedia.com/news/eleven-biotherapeutics-acquires-viventia-bio/#ixzz4SosSKlB7
Follow us: Investopedia on Facebook